Trial Profile
A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Fibrosis; Hepatitis C
- Focus Therapeutic Use
- Acronyms STREAGER
- 16 May 2019 Status changed from recruiting to completed.
- 14 Apr 2018 Results assessing the efficacy and safety of Elbasvir/Grazoprevir in HCV GT1b-infected patients (n=82), presented at The International Liver Congress 2018
- 25 Jan 2018 Planned End Date changed from 1 Oct 2017 to 1 Feb 2018.